Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Bridge formation by substitution
What ifWhat if intramolecular substitution forms the nitrogen bridge?
Claim language“reducing a compound of Formula (11)”
A cyclopentane precursor carries an aminomethyl tether and a sulfonate ester at the two prospective bridgeheads. The tethered amine displaces the sulfonate with inversion at the electrophilic carbon, forming the two-atom bridge of the 2-azabicyclo[2.2.1]heptane framework.
1.3Ring nitrogen protonation
What ifWhat if a ring ammonium salt controls the reactivity of the ring nitrogen during a compatible workup?
Claim language“a second protecting group”
Dilute aqueous citric acid protonates the ring nitrogen and transfers the carbamate-bearing intermediate into the aqueous phase. Potassium carbonate regenerates the neutral ring amine for extraction into an organic solvent.
1.1Ring nitrogen released by hydrolysis
What ifWhat if hydrolysis of an N-formyl precursor releases the bicyclic ring amine?
Claim language“reducing a compound of Formula (11)”
An N-formyl precursor carries the completed bicyclic framework and the exocyclic tert-butyl carbamate. Aqueous alkaline hydrolysis cleaves the ring nitrogen’s formyl group to give formate and the free bicyclic ring amine.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Bicyclic amine for polymer modification
The reduction of the doubly protected precursor supplies a bicyclic amine building block for specialty polymer research. The isolated product is converted to its free-base form and coupled through its exposed amine to pendant activated ester groups on a soluble polymer. The coupling forms amide bonds and leaves the protected amine on the pendant bicyclic group.
Component substitution
An ester solvent for reduction
Ethyl acetate replaces the alcohol as the reduction solvent. The free-base precursor and heterogeneous catalyst are charged to a stirred, pressure-rated vessel with ethyl acetate, and hydrogen is fed to the headspace. The catalyst is removed by filtration after precursor conversion, and the filtrate is concentrated for product isolation.
Parameter or scale variation
Parallel screening at two concentrations
Eight stirred, pressure-rated vessels each receive 0.10 mmol of the protected precursor. Four vessels receive 1.0 mL of solvent for a starting concentration of 0.10 mol/L, and four receive 2.0 mL for a starting concentration of 0.050 mol/L. Catalyst loading per mole of precursor, temperature, and hydrogen pressure are held constant, and chromatographic analysis compares conversion and product distribution at a common endpoint.
Combination with existing systems
Reduction with inline catalyst filtration
A stirred hydrogenation reactor feeds a closed pressure filter through a bottom outlet. After reduction and reactor depressurization, inert gas pressure transfers the slurry through the filter, which retains the heterogeneous catalyst. A solvent rinse displaces product solution from the filter cake, and the combined filtrate and rinse enter a separate isolation vessel.
Reduction connected to salt crystallization
A catalyst filter connects the reduction vessel to a jacketed batch crystallizer. The crystallizer receives the clarified solution and uses vacuum concentration and solvent exchange to set the solvent composition before adding a stoichiometric amount of a compatible acid. A seeded cooling cycle crystallizes the product salt, which is collected by filtration and washed with cold mother-liquor solvent.
Automated or data-driven variant
Chromatographic control of the reduction endpoint
An automated sampling loop withdraws liquid from the stirred reactor and passes it through a particulate filter before dilution and liquid chromatography. Software compares the measured precursor concentration with a preset limit and checks that the product concentration has stabilized across two successive samples. When both conditions are met, the controller closes the hydrogen feed and initiates controlled depressurization.
Specific version of a part
Diamine isolated as hydrochloride
Hydrogen chloride cleaves the tert-butyl carbamate to release the exocyclic primary amine. Excess acid protonates both nitrogen atoms, and concentration under acidic conditions recovers the diamine dihydrochloride.
Acid cleavable tert-butyl carbamate
A tert-butoxycarbonyl group masks an amino nitrogen as a carbamate. Acid treatment cleaves the tert-butyl group, and the resulting carbamic acid decarboxylates to release the amine.
Hydrogenolysis of benzyl carbamate
A benzyloxycarbonyl group masks an amino nitrogen as a benzyl carbamate. Hydrogen and palladium on carbon cleave the benzyl–oxygen bond, and decarboxylation releases the amine.
Tert-butyl carbamate formation
Di-tert-butyl dicarbonate converts the C4 primary amine to the tert-butyl carbamate while the ring nitrogen carries a benzyloxycarbonyl group. Hydrogenolysis then releases the ring nitrogen and furnishes the target carbamate.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1reducing a compound of Formula (11): or a salt thereof
The reduction of the carbonyl group of a compound according to formula (5), or salt thereof, for example by hydrogenation or by using a reducing agent known in the art (e.g. a hydride reagent such as sodium borohydride) forms a compound according to formula (1) or salt thereof.
A · US 8,993,785 B2 · ¶ 253
1.2wherein Pg1 is a first protecting group
This step can include further treatment with a suitable nitrogen de-protecting agent, for example Pd/C and hydrogen, when PG1 is neither acid not base labile N-protecting group.
A · US 8,993,785 B2 · ¶ 174
or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably a carboxyl group, comprising reducing a compound according to formula (5),
B · US 9,085,529 B2 · ¶ 39
1.3Pg2 is a second protecting group
1.4to form the compound of Formula (T-2).
Under this conditions, the reduction of the compound of formula (5a), or salt thereof, wherein R1 and R2 are defined as above, and R3 is CO2H, provides a composition comprising the compounds according to formulae (2a) and (2b), or salts thereof, wherein the molar ratio of compounds according to formula (2a), or salts thereof, to compounds according to formula (2b), or salts thereof, is at least 51 to 49, such as 54 to 46.
B · US 9,085,529 B2 · ¶ 51
An empty cell means only that no passage was reproduced there.
Statements in these documents
wherein R1 is hydrogen or a nitrogen protecting group, as defined herein, methods for their preparation and their use in the preparation of NEP-inhibitors, particularly in the preparation of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester, or salt thereof.
A · US 8,993,785 B2 · ¶ 3
The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone.
B · US 9,085,529 B2 · ¶ 1
Compounds of formula (2) can be used as intermediates in the preparation of NEP inhibitors, or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-5-biphenyl-α-methylalkanoic acid, or acid ester, backbone, preferably N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenyl phenyl methyl)-4-amino-(2R)-methyl butanoic acid ethyl ester, for example, as described in the Journal of Medicinal Chemistry, 1995, 38, 1689.
B · US 9,085,529 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0356805 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356805/, SHA-256 a72822f3fa2af6e7581d24f46a05bdabb9d7e65d4760f8abb1ed563b399d4ce0